Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGX is a soluble viscous fiber, specifically an alginate-konjac-xanthan polysaccharide complex, developed by InovoBiologic Inc. and associated with Factors Group of Companies. It is designed as an adjunct to intensive weight management programs, particularly for adults with type 2 diabetes and overweight/obesity. PGX beneficially affects metabolism by improving glycemic control (reducing HbA1c), promoting weight loss, decreasing waist circumference, and lowering LDL cholesterol. Its mechanism involves modulating gut microbiota, specifically increasing the relative abundance of beneficial bacteria such as *Collinsella*, *Parabacteroides*, and *Roseburia*, and influencing short-chain fatty acid production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PGX.